Your session is about to expire
← Back to Search
Behavioural Intervention
Counseling for Hereditary Breast or Ovarian Cancer Risk
N/A
Waitlist Available
Led By Bita Nehoray
Research Sponsored by City of Hope Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up one week after genetic cancer risk assessment (gcra)
Awards & highlights
No Placebo-Only Group
Summary
This trial looks at a new way to help Latinas at high risk for hereditary breast or ovarian cancer learn more about their risk.
Who is the study for?
This trial is for Latinas at high risk for hereditary breast or ovarian cancer who meet criteria for genetic testing. Participants must understand English or Spanish, be willing to consent, and can include pregnant women. It's aimed at those from low-income communities who are under- or uninsured.
What is being tested?
The study tests a culturally-informed counseling intervention designed to educate high-risk Latina women about their cancer risks. It involves completing questionnaires and surveys, receiving educational materials, and participating in counseling sessions.
What are the potential side effects?
Since this trial focuses on non-medical interventions like counseling and education rather than drugs or medical procedures, it does not have typical side effects associated with clinical trials that test medications.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ one week after genetic cancer risk assessment (gcra)
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~one week after genetic cancer risk assessment (gcra)
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Conduct a randomized controlled trial of a culturally-informed pre-GCRA telephone intervention utilizing AMI techniques
Anxiety
Side effects data
From 2017 Phase 2 trial • 14 Patients • NCT0173244586%
Platelet count decreased
64%
Anemia
36%
White blood cell decreased
29%
Neutrophil count decreased
21%
Diarrhea
21%
Nausea
14%
Edema limbs
14%
Alanine aminotransferase increased
14%
Pain in extremity
14%
Hyperkalemia
14%
Hyponatremia
7%
Anorexia
7%
Hypertension
7%
Upper respiratory infection
7%
Urinary tract infection
7%
Irregular menstruation
7%
Myocardial infarction
7%
General disorders and administration site conditions - Other, specify
7%
Sudden death NOS
7%
Lung infection
7%
Intracranial hemorrhage
7%
Transient ischemic attacks
7%
Premature menopause
7%
Periorbital edema
7%
Photosensitivity
100%
80%
60%
40%
20%
0%
Study treatment Arm
Supportive Care (Ruxolitinib Phosphate and Danazol)
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
3Treatment groups
Experimental Treatment
Active Control
Group I: Arm IIExperimental Treatment3 Interventions
Patients participate in a controlled condition comprising a health habits intervention group.
Group II: Arm IExperimental Treatment4 Interventions
Patients receive a culturally-informed adapted motivational interviewing telephone call.
Group III: Arm IIIActive Control2 Interventions
Patients receive usual care comprising a standard scheduling phone call and proceed with normal GCRA process.
Find a Location
Who is running the clinical trial?
City of Hope Medical CenterLead Sponsor
602 Previous Clinical Trials
1,923,087 Total Patients Enrolled
National Cancer Institute (NCI)NIH
13,924 Previous Clinical Trials
41,017,458 Total Patients Enrolled
Bita NehorayPrincipal InvestigatorCity of Hope Medical Center
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You have participated in genetic counseling and testing for cancer risk before.You have a history of inherited breast or ovarian cancer.Women who identify as being of Latino or Hispanic background.Women who do not have health insurance and are from low-income areasYou meet the criteria for getting genetic testing for hereditary breast cancer according to the National Comprehensive Cancer Network (NCCN).
Research Study Groups:
This trial has the following groups:- Group 1: Arm II
- Group 2: Arm III
- Group 3: Arm I
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Share this study with friends
Copy Link
Messenger